These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 25519148

  • 1. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [Abstract] [Full Text] [Related]

  • 2. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, Mimura K, Takahashi K, Takahashi T, Kurachi H, Kimura T.
    Clin Cancer Res; 2011 Jul 01; 17(13):4462-73. PubMed ID: 21622721
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
    Chen MB, Wu XY, Tao GQ, Liu CY, Chen J, Wang LQ, Lu PH.
    Int J Cancer; 2012 Dec 01; 131(11):2487-98. PubMed ID: 22438101
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB, Honig A, Schönhals T, Weidler C, Häusler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J.
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov 01; 141(1):64-9. PubMed ID: 18687514
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J, Zhang L, Zhang X, Xing X.
    J Chemother; 2015 Nov 01; 27(6):358-64. PubMed ID: 25976336
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.
    Int J Oncol; 2012 Nov 01; 41(5):1845-54. PubMed ID: 22922893
    [Abstract] [Full Text] [Related]

  • 20. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 01; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.